How much is the latest price of a box of Ripotinib in 2025?

Repotrectinib is a highly selective anti-tumor drug that targets ROS1 and NTRK gene fusion. It is widely used to treat ROS1-positive non-small cell lung cancer (NSCLC) and some patients with NTRK fusion tumors. The drug has been officially launched in China in 2024 and has been included in the national medical insurance directory, marking a significant increase in its accessibility in the domestic market. It is an efficient and sustainable treatment option, especially for patients who have failed multiple lines of treatment.

In terms of specific applications, Ripotinib is administered in the form of oral capsules. The conventional specification is 40 mg. Each box contains 120 capsules. It is simple and convenient to take and easy to manage at home. Before use, patients need to undergo professional genetic testing to confirm whether there is a ROS1 or NTRK fusion mutation, so as to accurately match the target of the drug and ensure maximum efficacy. Due to its structural advantages, Ripotinib has outstanding performance in controlling brain metastasis and treating drug-resistant mutations. It is especially suitable for patients who are resistant to other ROS1 or NTRK-targeted drugs.

As for the selling price, the original version of Ripotinib currently on the market in China is sold by regular pharmaceutical companies. The price of each box of 40mg*120 tablets is about 5,000 yuan. With the support of medical insurance policies, the actual payment burden of patients has dropped significantly. Medical insurance policies vary slightly from place to place. In addition, some patients also obtain generic versions through overseas channels such as Laos. The ingredients of such products are similar to the original drugs, and the price is aboutaround 2,000 yuan. However, they need to pay attention to the quality standards, supervision and risk factors of generic drugs.

Overall, the launch of repotinib brings new treatment hope to ROS1-positive lung cancer patients, and reasonable prices and medical insurance support make it more accessible. As its indications continue to expand in the future, this drug is expected to become one of the core options for the treatment of more solid tumors

Reference materials:https://www.drugs.com/mtm/repotrectinib.html